XALKORI® (crizotinib): Indications in advanced NSCLC

XALKORI  as monotherapy is indicated for:

An accurate and validated assay for either ALK or ROS1 is necessary for the selection of patients for treatment with XALKORI.1
For optimal treatment, international guidelines recommend reflex ALK and ROS1 testing.1,2

References:
1. XALKORI Summary of Product Characteristics
2. Planchard D, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2018: 29(supplement 4):iv192-iv237. doi:10.1093/annonc/mdy275
3. National Institute for Health and Care Excellence. NICE guidance: crizotinib (Xalkori). Available at: https://www.nice.org.uk/guidance/ta406. Last accessed: June 2018
4. Scottish Medicines Consortium. SMC advice: crizotinib (Xalkori). Available at: https://www.scottishmedicines.org.uk/medicines-advice/crizotinib-xalkori.... Last accessed: June 2018
5. Zykadia® Summary of Product Characteristics 
6. Alecensa® Summary of Product Characteristics 

PP-XLK-GBR-1134. March 2020